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Vitamin D insufficiency is common, correctable, and influenced by genetic factors, and it has been associated with risk of several dis-
eases. We sought to identify low-frequency genetic variants that strongly increase the risk of vitamin D insufficiency and tested their
effect on risk of multiple sclerosis, a disease influenced by low vitamin D concentrations. We used whole-genome sequencing data
from 2,619 individuals through the UK10K program and deep-imputation data from 39,655 individuals genotyped genome-wide.
Meta-analysis of the summary statistics from 19 cohorts identified in CYP2R1 the low-frequency (minor allele frequency ¼ 2.5%) syn-
onymous coding variant g.14900931G>A (p.Asp120Asp) (rs117913124[A]), which conferred a large effect on 25-hydroxyvitamin D
(25OHD) levels (0.43 SD of standardized natural log-transformed 25OHD per A allele; p value ¼ 1.5 3 1088). The effect on 25OHD
was four times larger and independent of the effect of a previously described common variant near CYP2R1. By analyzing 8,711 indi-
viduals, we showed that heterozygote carriers of this low-frequency variant have an increased risk of vitamin D insufficiency (odds ratio
[OR]¼ 2.2, 95% confidence interval [CI]¼ 1.78–2.78, p¼ 1.263 1012). Individuals carrying one copy of this variant also had increased
odds of multiple sclerosis (OR ¼ 1.4, 95% CI ¼ 1.19–1.64, p ¼ 2.63 3 105) in a sample of 5,927 case and 5,599 control subjects.
In conclusion, we describe a low-frequency CYP2R1 coding variant that exerts the largest effect upon 25OHD levels identified to date
in the general European population and implicates vitamin D in the etiology of multiple sclerosis.Introduction
Vitamin D insufficiency affects approximately 40% of the
general population in developed countries.1 This could
have important public health consequences, given that
vitamin D insufficiency has been associated with muscu-
loskeletal consequences and several common diseases,
such as multiple sclerosis (MIM: 126200), type 1 diabetes
(MIM: 222100), type 2 diabetes (MIM: 125853), and
several cancers.2 Further, repletion of vitamin D status
can be achieved safely and inexpensively. Thus, under-
standing the determinants of vitamin D insufficiency,
and their effects, can provide a better understanding of
the role of vitamin D in disease susceptibility with poten-
tially important public health benefits.1Department of Human Genetics, McGill University, Montreal, QC H3A 1B1, C
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 2017 American Society of Human Genetics.Approximately half of the variability in the concentra-
tion of the widely accepted biomarker for vitamin D sta-
tus, 25-hydroxyvitamin D (25OHD), has been attributed
to genetic factors in twin and family studies.3,4 Four com-
mon (minor allele frequency [MAF] > 5%) genetic vari-
ants in loci near four genes known to be involved in
cholesterol synthesis (DHCR7 [MIM: 602858]), hydroxyl-
ation (CYP2R1 [MIM: 608713]), vitamin D transport
(GC [MIM: 139200]), and catabolism (CYP24A1 [MIM:
126065]) are strongly associated with 25OHD levels
yet explain little of its heritability.5 Low-frequency and
rare genetic variants (defined as those with a MAF %
5% and 1%, respectively) have recently been found
to have large effects on clinically relevant traits,6–8
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Therefore, the principal objective of the present study
was to detect low-frequency and rare variants with large ef-
fects on 25OHD levels through a large-scale meta-analysis
and describe their biological and clinical relevance. Similar
to an earlier genome-wide association study (GWAS) exam-
ining common (MAF R 5%) genetic variation by the
SUNLIGHT consortium,5 we sought to increase under-
standing of the genetic etiology of vitamin D variation
within the general population; however, our current study
focused on genetic variation with a MAF < 5%. This has
only recently been made possible through whole-genome
sequencing (WGS) and the use of improved genotype
imputation for low-frequency and rare variants with the
recent availability of large WGS reference panels.9 The sec-
ond objective of this study was to better understand
whether low-frequency genetic variants with large effects
on 25OHD could predict a higher risk of vitamin D insuf-
ficiency in their carriers and whether vitamin D intake
through diet might interact with such genetic factors to
prevent, or magnify, vitamin D insufficiency. Finally, we
sought to understand whether these genetic determinants
of 25OHD levels are implicated in multiple sclerosis, a dis-
ease influenced by low 25OHD levels.10
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228 The American Journal of Human Genetics 101, 227–238, Augusttify novel genetic determinants of vitamin D in 42,274
individuals. We next tested if these genetic variants
conferred a higher risk of vitamin D insufficiency in
8,711 subjects and whether this insufficiency showed ef-
fect modification by dietary intake. Last we assessed their
effect on multiple sclerosis in a separate sample of 5,927
case and 5,599 control subjects.Material and Methods
Cohorts
Allhumanstudieswereapprovedbyeach respective institutional or
national ethics review committee, and all participants provided
written informed consent. To investigate the role of rare and low-
frequency genetic variation on 25OHD levels in individuals of Eu-
ropean descent, we usedWGS data at amean read depth of 6.73 in
2,619 subjects from twocohortswith available25OHDphenotypes
in theUK10Kproject11 (Table1).Wealsoused imputation reference
panels to impute variants that were missing, or poorly captured,
from previous GWASs of 39,655 subjects (Table 1 and Figure 1).
The participating individuals were drawn from independent co-
horts of individuals of European descent. A detailed description
of each of the participating studies is provided in Table S1.25OHD Measurements
The methods applied for measuring 25OHD levels differed among
the participating cohorts (Tables S1 and S6). The four methodsent of Internal Medicine, Leiden University Medical Center, Leiden 2333 ZA,
al Health, McGill University, Montreal, QCH3A 1A2, Canada; 20Department
ular Health Research Unit, Departments of Medicine and Biostatistics, Uni-
earch Unit, Departments of Medicine, Epidemiology, and Health Services,
ington Health Research Unit, Seattle, WA 98101, USA; 24Institute for Trans-
Institute, Torrance, CA 90502, USA; 25Department of Pediatrics, Harbor-
, Perelman School of Medicine, University of Pennsylvania, Philadelphia,
hildren’s Hospital of Philadelphia, Philadelphia, PA 19104, USA; 28Menzies
Tasmania 7000, Australia; 29Geriatric Medicine, Institute of Medicine, Sahl-
iatric Medicine, Sahlgrenska University Hospital, 43180 Mölndal, Sweden;
Sciences, Lund University, 22241 Malmö, Sweden; 32Department of Ortho-
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Table 1. Participating Cohorts and Number of DNA Samples per
Cohort
Study Imputed
Whole-Genome
Sequenced
ALSPAC 3,679 1,606
TUK 1,919 1,013
Generation R 1,442 –
BPROOF 2,514 –
FHS 5,402 –
MrOS 3,265 –
RSI 3,320 –
RSII 2,022 –
RSIII 2,913 –
CHS 1,792 –
BMDCS 863 –
MrOS GBG 945 –
GOOD 921 –
MrOS Malmo 893 –
PIVUS 943 –
ULSAM 1,095 –
NEO 5,727 –
Total 39,655 2,619used were tandem mass spectrometry (in the Bone Mineral Den-
sity in Childhood Study [BMDCS], Osteoporotic Fractures in
Men USA [MrOS], and B-Vitamins for the Prevention of Osteopo-
rotic Fractures [BPROOF]), combined high-performance liquid
chromatography and mass spectrometry (in the Avon Longitudi-
nal Study of Parents and Children [ALSPAC], BPROOF, Cardiovas-
cular Health Study [CHS], Upssala Longitudinal Study of Adult
Men [ULSAM], Netherlands Epidemiology of Obesity [NEO], and
Generation R Study [Generation R]), chemiluminescence immu-
noassay (DiaSorin) (in TwinsUK [TUK], the Prospective Investiga-
tion of the Vasculature in Upssala Seniors [PIVUS], the Framing-
ham Heart Study [FHS], Osteoporotic Fractures in Men Malmo
[MrOS Malmo], Osteoporotic Fractures in Men Gothenburg
[MrOS GBG], and Gothenburg Osteoporosis and Obesity Determi-
nants [GOOD]), and electrochemiluminescence immunoassay
(COBAS, Roche Diagnostics) (in Rotterdam Studies I [RSI], II
[RSII], and III [RSIII]). Detection limits for the different methods
are provided in Table S6.
WGS, Genotyping, and Imputation
ALSPAC WGS and TUK WGS cohorts had been sequenced at an
average read depth of 6.73 through the UK10K consortium on
the Illumina HiSeq platform and aligned to the GRCh37 human
reference sequence with Burrows-Wheeler Aligner 31.12 Single-
nucleotide variant (SNV) calls were completed with SAMtools/
BCFtools,13 and VQSR14 and GATK were used to recall these vari-
ants. WGS for the ALSPAC and TUK cohorts has been described
in detail in a previous publication from our group.7 Table S8 sum-
marizes the data-generationmethod for sequencing-based cohorts.
Participating studies separately genotyped samples and imputed
them toWGS-based reference panels. The most recent imputationThe Americpanels, such as the UK10K and 1000 Genomes Project (v.3) com-
bined panel (7,562 haplotypes from the UK10K project and
2,184 haplotypes from the 1000 Genomes Project9) and the
Haplotype Reference Consortium (HRC) panel (64,976 haplo-
types15), enabled more accurate imputation of low-frequency var-
iants than the UK10K or 1000 Genomes reference panel alone.9
Specifically, 11 of the 17 participating cohorts were imputed to
the combined UK10K and 1000 Genomes reference panel (total
number of imputed individuals included in the meta-analysis ¼
25,589). Three of the participating cohorts were imputed with
the HRC panel (n ¼ 5,717). Finally, two cohorts were imputed to
the 1000Genomes panel (n¼ 7,536), and one cohort was imputed
to the UK10K panel (n ¼ 863) (Table S1). Details on genotyping
methods and imputation for the 17 participating cohorts are pre-
sented in Table S6. Info scores for the imputed SNVs per partici-
pating cohort are presented in Table S7. To assess the quality of
imputation, we tested the non-reference discordance rate for the
low-frequency genome-wide-significant SNVs and found this to
be 0% (Table S9).Association Testing for 25OHD Levels and Meta-analysis
We conducted a GWAS separately for each cohort by using an addi-
tive genetic model for 25OHD levels. Because 25OHD concentra-
tions were measured by different methods, log-transformed
25OHD levels were standardized to Z scores after adjustment for
age, sex, BMI, and season of measurement. Specifically, the pheno-
type for each GWASwas prepared according to the following steps:
(1) We log transformed 25OHD levels to ensure normality. (2) We
used linear regression models to generate cohort-specific residuals
of log-transformed 25OHD levels adjusted for covariates (age, sex,
BMI, and season). Season was treated as a non-ordinal categorical
variable (summer: July to September; fall: October to December;
winter: January to March; and spring: April to June). (3) We added
themeanof log-transformed25OHDlevels to the residuals to create
the adjusted 25OHDphenotype. (4)We thennormalized the above
phenotype within each cohort (mean of 0 with 1 SD) to make the
phenotype consistent across cohorts, given that our consortium
has measured 25OHD levels in different cohorts by different
methods. (5) Finally, we removed outliers beyond 5 SD from step 4.
For comparison purposes, we computed the average 25OHD
levels, adjusted for age, sex, BMI, and season of measurement, in
one cohort of our meta-analysis (TUK WGS) in carriers and non-
carriers of the lead SNV(s).
The software used for each cohort’s GWAS is listed in Table S1.
We performed single-variant tests for variants with MAF > 0.1%
by using an additive effect of the minor allele at each variant in
each cohort. The type of software employed for single-variant
testing for each cohort is shown in Table S1. Studies with related
individuals used software that accounted for relatedness. Cohort-
specific genomic inflation factors (lambda values) are also shown
in Table S1 (the mean lambda value was 1.015).
We then meta-analyzed association results from all discovery
cohorts (n ¼ 42,274). This stage included validation of the
results file format, filtering files by the above quality-control
(QC) criteria, comparison of trait distributions among different
studies, and identification of potential biases (large beta values
and/or standard errors, inconsistent effect allele frequencies,
and/or extreme lambda values). Meta-analysis QC of the GWAS
data included the following SNV-level exclusion criteria: (1) infor-
mation score < 0.4, (2) Hardy-Weinberg equilibrium (HWE)
p value < 106, (3) missingness > 0.05, and (4) MAF < 0.5%.an Journal of Human Genetics 101, 227–238, August 3, 2017 229
Figure 1. Schematic of the Discovery
Single-Variant Meta-analysisSNValignment across studies was done with the chromosome and
position information for each variant according to genome build
hg19 (UCSC Genome Browser). SNVs in the X chromosome
were not included in the meta-analysis. Fixed-effects meta-anal-
ysis was performed with the software package GWAMA16 with
adjustment for genomic control. We tested bi-allelic SNVs with
MAF R 0.5% for association and declared genome-wide statistical
significance at p % 1.2 3 108 for variants present in more than
one study. This stringent p value threshold was set to adjust for
all independent SNVs above the MAF threshold of 0.5%.17
Conditional analysis was undertaken for the four previously
described lead vitamin D SNVs from the SUNLIGHT consortium
with the Genome-wide Complex Trait Analysis (GCTA) pack-
age.18 This method uses an approximate conditional-analysis
approach from summary-level statistics from the meta-analysis
and inter-SNV linkage-disequilibrium corrections estimated from
a reference sample. We used UK10K individuals as the reference
sample to calculate the linkage disequilibrium of SNVs. The
associated regions flanking within 400 kb of the top SNVs from
SUNLIGHTwere extracted, and the conditional analyses were con-
ducted within these regions. Conditional analyses of individual
variants presented in Tables 2 and S5 were conducted with
GCTA v.0.93.9 and default parameters.
We used analyses of haplotype blocks for the candidate variants
of interest by deriving phased haplotypes from 1,013 individuals
from the TUK WGS cohort with a custom R package.
Effects on Vitamin D Insufficiency
To investigate the effect of genome-wide-significant SNVs on
vitamin D insufficiency (defined as 25OHD levels below
50 nmol/L), we used data from four cohorts: TUK imputed, TUK
WGS, BPROOF, and MrOS (n ¼ 8,711). We performed logistic
regression of this binary phenotype against the SNVs by adjusting
for the following covariates: age, sex, BMI, and season of measure-
ment. Meta-analysis of cohort-level summary statistics was per-
formed in R19 with the epitools20 and metafor21 packages.
Interaction Analysis with Vitamin D Intake
We analyzed interactions between our candidate SNV(s) and
vitaminDdietary intake (continuous and tertiles) in 9,224 individ-230 The American Journal of Human Genetics 101, 227–238, August 3, 2017uals from five of the cohorts (FHS, PIVUS,
ULSAM, BPROOF, and RSIII) participating
in our discovery phase. A detailed descrip-
tion of the method for capturing vitamin
D intake in each of the participating co-
horts appears in Table S6. Linear regression
was conducted in each of these studies
under an additive genetic model. The
following variables and co-variables were
included in the model: log-transformed
serum 25OHD as the dependent variable;
SNV genotype (coded as 0, 1, or 2) as an
independent variable; SNV (genotype) 3
dietary vitamin D intake (continuous or
tertiles) as an interaction term; and age,
sex, BMI, season of 25OHD measurement,dietary vitamin D intake (continuous or tertiles), supplemented
vitaminD (yes or no), and total energy intake as covariates. The re-
sults from the five studies were meta-analyzed by a fixed-effects
model with the metafor tool of the R statistical package.
Effects on Multiple Sclerosis
We tested the effect of the genome-wide-significant SNVs on the
risk of multiple sclerosis in 5,927 case and 5,599 control samples
by assuming an additive genetic model. Control samples were
obtained from the UK Biobank22 by random selection of partici-
pants without multiple sclerosis. Case samples were obtained
from the UK Biobank,22 previously published multiple sclerosis
GWASs,23,24 and newly genotyped UK subjects. Before genotype
imputation of the genotyped case samples, we applied
numerous QC criteria to ensure unbiased genotype calls between
cohorts. These included retaining only SNVs with a MAF > 1%
and excluding SNVs or samples with high missingness.25
Further, samples were assessed for population stratification with
EIGENSTRAT,26,27 and outliers were removed. Genotype data
were then imputed by the Sanger Imputation Service15 with
the combined UK10K and 1000 Genomes Phase 3 reference
panels,9,28 the same reference panel used for the UK Biobank con-
trol samples. Genotype data were phased with EAGLE229 and
imputed with PBWT.30 SNPTEST31 was used for association testing
on the combined case-control dataset, which included testing the
additive effect of each allele on multiple sclerosis status and using
the top ten principal components from EIGENSTRAT26,27 to adjust
for population stratification and batch effects.
Results
GWAS
After strict QC, the genomic inflation factor for the meta-
analysis of 19 GWASs was 0.99, suggesting a lack of bias
due to population stratification (Figure 2). Through meta-
analysis of 11,026,511 sequenced and imputed variants
from our discovery cohorts (Table 1), we identified a signal
at the chromosomal locus 11p.15.2, which harbors vari-
ants associated with 25OHD levels (lead low-frequency
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The AmericSNV g.14900931G>A [p.Asp120Asp] [rs117913124(A)]
[GenBank: NC_000011.9]; MAF ¼ 2.5%, allelic effect
size ¼ 0.43 SD of the standardized log-transformed
25OHD levels [SD], p ¼ 1.5 3 1088; Figure 3 and Table 2).
The direction of effect was consistent across all discovery
cohorts (Table 3 and Figure 3A), and the mean imputation
information score for the imputed studies was 0.97. This
low-frequency synonymous coding variant is in exon 4
of CYP2R1 and is 14 kb from the previously identified
common CYP2R1 variant rs10741657 (r2 between these
two SNVs ¼ 0.03) (Figure 4). To our knowledge,
rs117913124 has not previously been associated with any
vitamin-D-related traits in humans.
Figure S1 shows a comparison of the average 25OHD
levels, adjusted for age, sex, BMI, and season of measure-
ment, in non-carriers and heterozygous carriers of the A
allele of rs117913124 in the TUKWGS cohort. The average
25OHD levels, adjusted for age, sex, BMI, and season of
measurement were computed in 542 individuals from
the TUK WGS cohort, among which 510 were not carriers
and 32 were heterozygous carriers of the A allele of
rs117913124 (no homozygous carriers were present in
this cohort). After removing outliers (adjusted 25OHD
levels 53 SD from the mean), we included in our analysis
449 non-carriers and 30 heterozygous carriers (for a total
of 479 individuals). A linear-regression model with the
adjusted 25OHD levels as the dependent variable and
the dose of the A allele of rs117913124 (numeric factor 1
or 0) as the independent variable demonstrated an
8.3 nmol/L decrease in the adjusted 25OHD levels per A
allele. The mean adjusted 25OHD levels were 64.3 nmol/L
in non-carriers and 56.0 nmol/L in heterozygous carriers.
Two-way conditional analysis between the CYP2R1
common (rs10741657) and low-frequency (rs117913124)
variants revealed that the two association signals are
largely independent. Specifically, after conditioning on
rs10741657, rs117913124 remained strongly associated
with 25OHD levels (pcond ¼ 2.4 3 1078); after condition-
ing on rs11791324, the effect of rs10741657 on 25OHD
levels remained significant (pcond ¼ 4.0 3 1033 versus
ppre-cond ¼ 8.8 3 1045; Tables 2 and S5). Further, no
other low-frequency variant in the region remained signif-
icant after conditioning on rs117913124 (Table 2). To
further disentangle the role of rs117913124 from that
of rs10741657 on 25OHD levels, we undertook a
haplotype analysis based on WGS data from 3,781 indi-
viduals from the TUK WGS and ALSPAC WGS cohorts.
We found that the 25OHD decreasing A allele of
rs117913124 was always transmitted in the same haplo-
type block with the 25OHD decreasing G allele of the com-
mon CYP2R1 variant rs10741657. By using 25OHD data
from the TUK WGS cohort, we compared the 25OHD
levels among carriers of the various haplotype blocks. We
observed lower levels of 25OHD in carriers of the A allele
of rs117913124 than in non-carriers, independently of
the presence of the effect allele G of the common
CYP2R1 variant (Table 4).an Journal of Human Genetics 101, 227–238, August 3, 2017 231
Figure 2. Discovery Single-Variant Meta-analysis
(A) Quantile-quantile plot for the single SNV meta-analysis.
(B) Manhattan plot of the meta-analysis depicts variants with MAF > 0.5% across the 22 autosomes against the log10 p value from the
meta-analysis of 19 cohorts, which included 42,274 individuals.No other low-frequency or rare variants were identified
in the three previously described vitamin-D-related loci
at DHCR7, GC, and CYP24A1. The mean effect size of the
four previously reported common (MAF R 5%) genome-
wide-significant SNVs from the SUNLIGHT consortium
was 0.13 SD, and the largest effect size was 0.25 SD
(for the GC variant) in our meta-analysis (Table S3 and
Figure 3B). The effect size of rs10741657(G), the known
common CYP2R1 variant, was 0.09 SD. Hence, the
observed effect size of rs117913124 is 3-fold larger thanA
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Figure 3. Forest Plot by Cohort for rs117913124 and Forest Plot f
Related Variants from Discovery Meta-analysis
(A) Forest plot of estimates from all 19 studies for the low-frequency
(B) Forest plot of the effect of the four common SUNLIGHT variants
formed 25OHD levels.
Squares represent beta values in the 19 studies, and bars around the
232 The American Journal of Human Genetics 101, 227–238, Augustthe above mean, 4-fold larger than that of the common
CYP2R1 variant, and almost twice that of the largest previ-
ously reported effect of theGC variant. Last, the percentage
of the 25OHD phenotype variance explained by the low-
frequency CYP2R1 variant (0.9%) was more than double
the percentage of the variance explained by the CYP2R1
common variant (0.4%).
We also identified 18 genome-wide-significant low-fre-
quency and rare SNVs on the same chromosome 11 region
as rs117914124 in the neighboring PDE3B (MIM: 602047)B
–
–
–
–
–
– – –
– –
– –
– –
– –
– –
or rs117913124 and the Previously Described Common 25OHD-
CYP2R1 variant rs117913124.
and the CYP2R1 low-frequency variant rs117913124 on log-trans-
squares represent 95% confidence intervals (CIs).
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Table 3. Summary Statistics for the CYP2R1 Low-Frequency Variant, rs117913124, from 19 Studies
Study
25OHD Measurement
Method n EAF (A Allelea) Betab Standard Error p Value Information Score
ALSPAC imputed MS 3,675 0.028 0.59 0.07 3.43 3 1018 0.99
ALSPAC WGS MS 1,606 0.028 0.65 0.11 8.23 3 1010 NA
BPROOF MS 2,512 0.027 0.4 0.09 4.99 3 106 0.97
BMDCS MS 863 0.019 0.11 0.06 0.058 0.98
CHS MS 1,581 0.022 0.55 0.11 5.15 3 107 0.88
FHS CLIA 5,402 0.021 0.45 0.07 2.32 3 1010 0.97
GenerationR MS 1,442 0.033 0.66 0.1 1.78 3 106 1
GOOD CLIA 921 0.028 0.14 0.14 0.31 0.96
MrOS MS 3,265 0.018 0.76 0.09 5.63 3 1016 0.96
MrOS Malmo CLIA 893 0.033 0.33 0.14 0.016 0.94
MrOS GBG CLIA 945 0.026 0.61 0.14 7.87 3 106 1
NEO MS 5,727 0.025 0.54 0.06 2.73 3 1019 1
PIVUS CLIA 943 0.028 0.66 0.14 2.56 3 106 0.99
RSI ECLIA 3,320 0.025 0.19 0.08 0.019 0.98
RSII ECLIA 2,022 0.033 0.37 0.09 2.38 3 105 0.99
RSIII ECLIA 2,913 0.027 0.51 0.08 4.61 3 1010 0.98
TUK imputed CLIA 1,919 0.021 0.1 0.11 0.35 0.98
TUK WGS CLIA 1,013 0.025 0.39 0.14 0.006 NA
ULSAM MS 1,095 0.025 0.33 0.14 0.02 1
Abbreviations are as follows: CLIA, chemiluminescence immunoassay; EAF, effect allele frequency; ECLIA, electrochemiluminescence immunoassay; MS, mass
spectrometry; NA, not applicable; 25OHD, 25-hydroxyvitamin D.
aEffect allele is the 25OHD decreasing allele.
bBeta values represent changes in standard deviations of the standardized log-transformed 25OHD levels.(Tables 2 and S4 and Figure 4B). Signals from these SNVs
in PDE3B were independent of the common variant at
CYP2R1 (Table 2). We then created haplotype blocks with
rs117913124 and SNVs at PDE3B on the basis of haplotype
information from the 3,781 individuals from the TUKWGS
and ALSPAC WGS cohorts (Table S2). We found that the
25OHD decreasing allele (A) of rs117913124 was always in-
herited with the 25OHD decreasing allele (A) of its perfect
proxy rs116970203 (r2 ¼ 1). Therefore, rs116970203 is not
likely to have a distinct effect from that of rs117913124
on 25OHD levels. On the other hand, the 25OHD
decreasing alleles of the remaining four low-frequency
variants (all with a MAF of approximately 1.4%) were
not always inherited in the same haplotype block as
rs117913124 and rs116970203 and were in moderate link-
age disequilibrium with rs117913124 (all r2 < 0.6; Figures
4B and 4C). Each of the four alleles was in almost perfect
linkage disequilibrium with the remaining three (all r2 >
0.96). This implies that these four SNVs might influence
25OHD levels independently of rs117913124. Neverthe-
less, as mentioned above, after conditioning on the lead
low-frequency CYP2R1 SNV rs117913124, the p values of
the four PDE3B SNVs became non-significant and their
betavaluesdecreased substantially (Table 2), demonstratingThe Americthat they probably do not represent an independent signal
at the chromosome 11 locus.
rs117913124 and Risk of Vitamin D Insufficiency
To further investigate the clinical significance of the low-
frequency CYP2R1 variant rs117913124, we tested its ef-
fect on a binary outcome for vitamin D insufficiency
(defined as 25OHD levels < 50 nmol/L) in 8,711 individ-
uals from four studies (TUK WGS, TUK IMP, BPROOF,
and MrOS). rs117913124 was strongly associated with
an increased risk of vitamin D insufficiency (odds ratio
[OR] ¼ 2.20, 95% confidence interval [CI] ¼ 1.8–2.8, p ¼
1.2 3 1012) (Figure 5) after control for relevant covariates
as described in the Material and Methods.
Common 25OHD-Associated SNVs
We report two additional loci associated with 25OHD
levels (Table 5). Variants leading these associations were
common and exerted a rather small effect on 25OHD: (1)
a variant in chromosome 12 (rs3819817[C], intronic to
HAL [MIM: 609457]) with a MAF of 45%, a beta value of
0.04, and a p value of 3.23 1010; and (2) a variant in chro-
mosome 14 (rs2277458[G], intronic to GEMIN2 [MIM:
602595]) with a MAF of 21%, a beta value of 0.05, andan Journal of Human Genetics 101, 227–238, August 3, 2017 233
Figure 4. Association Signals from 11p.15.2
(A) UCSC Genome Browser snapshot including the top low-frequency SNVs (see Table 2) and the lead common variant rs10741657 in
CYP2R1. The position of rs117913124 is highlighted in light blue.
(B) Regional disequilibrium plot showing rs117913124 (purple dot), its perfect proxy rs11670203 (red dot), and the other genome-wide-
significant SNVs in the same locus (blue and green dots). The plot depicts SNVs within 1 Mb of a locus’s lead SNV (x axis) and their asso-
ciated meta-analysis p value (log10) (see Table S10 for more details). SNVs are color coded according to r2 with the lead SNV (labeled; r2
was calculated from the UK10K WGS dataset). The recombination rate (blue line), position of genes and their exons, and direction of
transcription are also displayed (below plot).
(C) Linkage-disequilibriumplot indicating the r2 values between the SNVs of Table 2 (top low-frequency variants) and between these low-
frequency SNVs and the lead common variant (rs107416570) at the same CYP2R1 locus (r2 calculated from the 1000 Genomes dataset).a p value of 6.0 3 109. Both variants were present in all
19 studies, and the direction of the effect was the same
among the 19 studies (Figure 6). Neither the HAL nor the
GEMIN2 locus is previously known to be associated with
25OHD levels. Of note, neither variant was present in
the HapMap imputation reference used in the SUNLIGHT
study.Interaction Analysis
CYP2R1 encodes the enzyme responsible for 25-hydroxyl-
ation of vitamin D in the liver,32 a necessary step in the
conversion of dietary vitamin D and vitamin D oral supple-
ments to the active metabolite, 1,25 dihydroxy-vitamin D.
Therefore, we hypothesized that, in contrast with non-
carriers, individuals heterozygous or homozygous for
rs117913124 in CYP2R1 would not show a response in
their 25OHD levels to vitamin D intake. In other words,
we expected carriers of the effect allele of rs117913124
to have steadily lower 25OHD levels, independently of234 The American Journal of Human Genetics 101, 227–238, Augusttheir vitamin D intake. To investigate this hypothesis, we
tested the presence of interaction between rs117913124
and vitamin D dietary intake (continuous values and
tertiles) on 25OHD levels in 9,224 individuals from
five studies (Figure S2). We found no interaction
between rs117913124 and dietary vitamin D intake (beta
value¼0.0002 and interaction p value¼ 0.41 for contin-
uous vitamin D intake; beta value ¼ 0.012 and p value ¼
0.60 for tertiles of vitamin D intake). Given that the two
common 25OHD-associated SNVs are located in genes
(HAL and GEMIN2) with no known role in the processing
of dietary vitamin D, we found no biological rationale for
undertaking a gene-diet interaction analysis for these
variants.25OHD-Assosiated Variants and Risk of Multiple
Sclerosis
We tested whether the CYP2R1 low-frequency variant
rs117913124 and the common variants rsrs3819817 and3, 2017
Figure 5. Effect of rs117913124 on Vitamin D Insufficiency
Forest plot of the effect of the low-frequency CYP2R1 variant
rs117913124 on vitamin D insufficiency in four studies. Squares
represent odds ratios for vitamin D insufficiency in the four
studies, and bars represent 95% CIs.
Table 4. Effect of Different Haplotype Combinations of the Low-
Frequency (rs117913124) and Common (rs10741657) CYP2R1
Variants on 25OHD Levels
Haplotypea Betab p Value n
GA GA 0.02 0.79 156
AG GA 0.49 0.02 23
AG GG 0.3 0.13 27
GA GG 0.01 0.87 477
GG GG 0.05 0.58 330
Results are based on individuals from the TUK WGS cohort.
aThe first allele in each chromatid corresponds to the low-frequency variant
rs117913124; the second allele corresponds to the common variant
rs10741657. The two AG blocks contain the 25OHD decreasing allele (A) of
the low-frequency variant, which is always inherited with the 25OHD
decreasing allele (G) of the common variant.
bBeta values represent changes in standard deviations of the standardized log-
transformed 25OHD levels.rs2277458 in HAL and GEMIN2, respectively, influence
the risk of multiple sclerosis. In 5,927 multiple sclerosis
samples and 5,599 control samples, we found that the
25OHD decreasing allele at rs117913124[A] was associated
with increased odds of multiple sclerosis (OR ¼ 1.40; 95%
CI ¼ 1.19–1.64; p value ¼ 2.6 3 105). By way of compar-
ison, the OR of multiple sclerosis for the common CYP2R1
variant was 1.03 (95% CI ¼ 0.97–1.08; p value ¼ 0.03) in
the same study and has previously been reported to be
1.05 (95% CI ¼ 1.02–1.09; p value 0.004) in a separate
study.33 Thus, the effect per allele of rs117913124 on mul-
tiple sclerosis was 12.4-fold larger than that attributed to
the already known common variant at CYP2R1. With re-
gard to the two common SNVs, the 25OHD decreasing
allele (T) at theHAL variant rs3819817 was not clearly asso-
ciated with risk of multiple sclerosis; however, there was a
trend in the expected direction: OR¼ 1.05 (95%CI¼ 1.00–
1.11; p value ¼ 0.07). We found no association between
the 25OHD decreasing allele (G) at the GEMIN2 variant
rs2277458 and risk of multiple sclerosis: OR ¼ 1.03 (95%
CI ¼ 0.96–1.11; p value ¼ 0.34).Discussion
In the largest GWAS meta-analysis of 25OHD levels in Eu-
ropean populations to date, we have identified a low-fre-
quency, synonymous coding genetic variant that has a
large effect and strongly associates with 25OHD levels.
This variant has an effect size 4-fold larger than that
described for the common variant in the same gene
(CYP2R1) and is associated with a 2-fold increase in risk
of vitamin D insufficiency and a 40% increase in the
odds of developing multiple sclerosis. The biological plau-
sibility of these findings is supported by the fact that the
low-frequency variant is located in CYP2R1, encoding the
major hepatic 25-hydroxylase for vitamin D.32 These find-
ings are of clinical relevance given that 5% of the general
European population carries this variant in either the ho-The Americmozygous or heterozygous state, and it is associated with
a clinically relevant increase in the risk of multiple
sclerosis.
Our study was enabled by large imputation reference
panels (UK10K-1000 Genomes and HRC) that offer at least
10-fold more European samples than the 1000 Genomes
reference panel alone. We did not identify genome-wide-
significant variants with a large effect on 25OHD in
novel genes in Europeans, although we did find variants
with smaller effects in two loci not previously known to
be associated with 25OHD. We also identified in a known
vitamin-D-related gene low-frequency variants with much
larger effects than those of the previously described com-
mon variants.
CYP2R1 encodes the enzyme that is responsible for
25-hydroxylation of vitamin D and is one of the
two main enzymes responsible for vitamin D hepatic
metabolism32 (Figure 7). Rare mutations in CYP2R1
have already been described to cause rickets (MIM:
27744).32,34 Given the important role of CYP2R1 in the
conversion of dietary vitamin D and vitamin D oral sup-
plements to the active form of vitamin D, we hypothe-
sized that carriers of the low-frequency CYP2R1 variant
might respond poorly to vitamin D replacement therapy.
We tested this hypothesis by undertaking an interaction
analysis between the CYP2R1 low-frequency variant and
dietary vitamin D intake, which showed no clear interac-
tion. However, we note that studies of gene-environment
interactions are generally underpowered, measurement
error in dietary data is common, and this interaction
was further limited by time differences between assess-
ment of dietary intake and measurement of 25OHD
levels. Therefore, whether this genetic variant influences
25OHD response to vitamin D administration requires
further study.
Although the aim of the present study was to
describe variants of low MAF and large effect on
25OHD, we report two common chromosome 12 (HAL)
and 14 (GEMIN2) variants that have a small effect
size and reached genome-wide significance in ouran Journal of Human Genetics 101, 227–238, August 3, 2017 235
Table 5. Main Findings of the GWAS Meta-analysis
SNP Chr Candidate Gene EA EAF Betaa p Value n
rs117913124 11 CYP2R1 A 0.025 0.43 1.5 3 1088 41,336
rs3819817 12 HAL C 0.45 0.04 3.2 3 1010 41,071
rs2277458 14 GEMIN2 G 0.21 0.05 6.0 3 109 39,746
Abbreviations are as follows: Chr, chromosome; EA, effect allele; EAF, effect allele frequency; SNP, single-nucleotide polymorphism.
aBeta values represent changes in standard deviations of the standardized log-transformed 25OHD levels while controlling for age, sex, BMI, and season of
measurement.meta-analysis. Although no existing evidence implicates
GEMIN2 in vitamin-D-related physiological pathways,
HAL is expressed in the skin and is involved in the for-
mation of urocanic acid, a ‘‘natural sunscreen.’’35,36
Thus, this could constitute a plausible pathophysiologic
mechanism implicating HAL in vitamin D synthesis
in the skin. Additional functional follow-up of the
signals in chromosomes 12 and 14 is needed to charac-
terize the genes and/or mechanisms underlying these
associations.
Our findings could have clinical relevance for several
reasons. First, individuals carrying at least one copy of
the low-frequency CYP2R1 variant have lower levels of
25OHD by a clinically relevant degree. Specifically, the
risk of vitamin D insufficiency is doubled in these individ-
uals. Second, their risk ofmultiple sclerosis is also increased
in accordance with previous evidence supporting a causal
role for vitamin D in the risk of multiple sclerosis.10 Third,
these findings affect 5% of individuals of European
descent. Fourth and finally, rs117913124 could be usedA B
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Figure 6. Association Signals from Chromosomes 12 and 14
Forest plots with (A) estimates for the chromosome 12 common vari
variant rs2277458 from all 19 studies of the meta-analysis where bo
studies, and bars around the squares represent 95% CIs.
236 The American Journal of Human Genetics 101, 227–238, Augustalong with the previously identified common vitamin-D-
related variants as an additional genetic predictor of low
25OHD levels inMendelian randomization studies investi-
gating the causal role of low vitamin D levels in human
disease.
Our study also has its limitations. First, although the
scope of our study was detection of low-frequency and
rare variants, we opted to include in our meta-analysis
two WGS studies with a relatively low read depth of
6.73, as well as three studies imputed to older imputa-
tion panels (1000 Genomes and UK10K). These studies
have a limited capacity to capture very rare variants,
which might explain why we failed to identify such asso-
ciations. In addition to the limitations arising from
the time difference between assessment of dietary
vitamin D intake and 25OHD measurements, the analysis
of the gene-diet interaction, as mentioned above, might
have lacked statistical power. Because our analysis
was restricted to populations of European ancestry, we
cannot make any assumptions concerning the effect of– –
–
–
– –
–
– – –
–––
– –
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–
–
–
–
–
–
–
–
–
–
–
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–
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– –
ant rs3819817 and (B) estimates for the chromosome 14 common
th variants were present. Squares represent beta values in the 19
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Figure 7. Schematic of the Vitamin D
Metabolic Pathway
UVB, ultraviolet B rays.rs117913124 in non-European populations. Nonetheless,
according to the 1000 Genomes reference, this variant
is rare in Africans (MAF ¼ 0.3%) and has not been
described in East Asians (MAF ¼ 0%). Therefore,
describing with any certainty the effect of this variant
on 25OHD levels in these populations will require
large sample sizes of these populations. Finally, in the
absence of functional experiments showing the exact
function of rs117913124 in CYP2R1 and given that this
synonymous polymorphism does not affect protein
sequence, we cannot unequivocally confirm that this
low-frequency variant is causal; however, given that this
is a coding variant in a well-documented 25OHD-associ-
ated gene, it seems likely that it exerts its effect on
CYP2R1.
In conclusion, our findings demonstrate the utility of
WGS-based discovery and deep imputation for enabling
the characterization of genetic associations, offering
an improved understanding of the pathophysiology of
vitamin D, providing an enriched set of genetic predictors
of 25OHD levels for future study, and enabling the identi-
fication of groups at increased risk for vitamin D insuffi-
ciency and multiple sclerosis.Accession Numbers
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